We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TAK-003

News List

Takeda’s dengue vaccine bags positive long-term efficacy results pharmatimes
May 26, 2021
Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 demonstrated continued protection through three years after vaccination, regardless of previous exposure to the disease.
EMA accepts regulatory submission for Takeda’s dengue vaccine candidate europeanpharmaceuticalreview
March 29, 2021
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.
Takeda and IDT Support Manufacturing of J&J’s COVID-19 Vaccine contractpharma
March 16, 2021
Takeda Pharmaceutical has entered a mutual agreement with IDT Biologika GmbH, a contract development and manufacturing organization (CDMO), to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture ...